Dr. Tam on Varying BTK Inhibitors in Mantle Cell Lymphoma

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, compares BTK inhibitors in mantle cell lymphoma (MCL).

For example, zanubrutinib in clinical use appears to have better tolerability compared with other BTK inhibitors, such as ibrutinib, explains Tam. Ongoing studies in other hematologic malignancies will further showcase the efficacy and safety of zanubrutinib in comparison to other BTK inhibitors.

The complete remission rates for zanubrutinib are encouraging, according to Tam, but since outcomes of zanubrutinib are being reported in 2 separate studies, it is difficult to compare definitively. Tam looks forward to seeing the long-term follow-up of zanubrutinib.